Featured Research

from universities, journals, and other organizations

Discovery goes from the lab to the patient

Date:
October 1, 2013
Source:
University of North Carolina School of Medicine
Summary:
A laboratory testing kit that estimates the risk of breast cancer relapse in spite of anti-hormone treatment has received approval from the U.S. Food and Drug Administration (FDA). This technology is based on a gene signature known as “PAM50”.

A laboratory testing kit that estimates the risk of breast cancer relapse in spite of anti-hormone treatment has received approval from the U.S. Food and Drug Administration (FDA). This technology is based on a gene signature known as "PAM50" originally discovered at UNC Lineberger Comprehensive Cancer Center by Chuck Perou, PhD, professor of genetics and pathology and UNC Lineberger member. Additional UNC inventors included Dr. Joel Parker, research assistant professor of genetics, and Dr. Maggie Cheang, a research associate in the Perou Lab.

"This approval marks more than a decade of work with my fellow researchers and highlights the growing importance of genomic and genetic tests in the oncology clinic," said Perou. "This test is the result of data coming from modern, cutting-edge genomic technologies, and thus it is exciting to see the bench to bedside story fulfilled."

A team of UNC researchers and collaborating researchers from three other institutions -- Washington University in St. Louis, the University of Utah and the BC Cancer Agency -- designed this test that categorizes breast tumors into one of four main subtypes by looking at the expression of 50 genes. The four types are luminal A, luminal B, HER2-enriched and basal-like. These subtype data are then combined with a standard pathology variable to deliver a "risk of recurrence" score that predicts the likelihood of that patient's disease returning within the next 10 years. In this way, clinicians may now be able to accurately identify those low risk patients for whom standard hormone therapy is sufficient.

"This is an amazing step in our focus on individualized treatment for our cancer patients," said Shelton Earp, MD, director at UNC Lineberger. "We are shifting from looking at the individual cells of a tumor to a sophisticated analysis into the genetics that drive this disease."

Patients with the luminal A subtype have a low risk of recurrence and do well with long-term anti-hormone therapy that reduces or blocks estrogen, which fuels these tumors. But the other tumor types may require more aggressive measures to prevent relapse, including chemotherapy and sometimes investigational drugs. "This is a very important step down the road towards personalized medicine, and our approach allows us to make this test available to a global market," said Perou.

The test, called ProsignaTM and manufactured by NanoString Technologies, comes with a machine and kit, so patients' tumor samples do not have to be sent to a single laboratory for analysis. Currently the test is being distributed to pathology labs around the world and also is approved for use in the European Union.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of North Carolina School of Medicine. "Discovery goes from the lab to the patient." ScienceDaily. ScienceDaily, 1 October 2013. <www.sciencedaily.com/releases/2013/10/131001123557.htm>.
University of North Carolina School of Medicine. (2013, October 1). Discovery goes from the lab to the patient. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2013/10/131001123557.htm
University of North Carolina School of Medicine. "Discovery goes from the lab to the patient." ScienceDaily. www.sciencedaily.com/releases/2013/10/131001123557.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins